Federal Rescheduling Set to Trigger Historic MSO Stock Surge
Cannabis rescheduling momentum builds as multi-state operators position for potential tax relief windfall that could spark biggest rally in three years.
Multi-state operators face a potential watershed moment as federal cannabis rescheduling discussions intensify, setting the stage for what analysts anticipate could be the sector's most explosive rally since the 2021 bull run. The regulatory shift would fundamentally alter the financial landscape for major MSOs including Curaleaf (CURLF), Green Thumb Industries (GTBIF), and Trulieve (TCNNF), which currently operate under severe federal tax disadvantages.
The primary catalyst centers on Section 280E tax relief, which currently prevents cannabis companies from deducting standard business expenses. This regulatory burden has compressed margins across the sector, with leading MSOs paying effective tax rates exceeding 70% in some cases. Rescheduling cannabis from Schedule I to Schedule III would eliminate these restrictions, potentially boosting EBITDA margins by 15-25 percentage points for established operators.
Current market conditions mirror the setup that preceded 2021's historic cannabis rally, when retail investor enthusiasm and legislative optimism drove the AdvisorShares Pure US Cannabis ETF (MSOS) up over 100% in six months. Today's compressed valuations create similar upside potential, with most major MSOs trading at enterprise value-to-sales multiples below 2x despite generating positive cash flows and expanding market share in key states.
The regulatory momentum extends beyond federal rescheduling, as additional states prepare adult-use programs and existing markets mature. Florida's upcoming ballot initiative alone represents a $6 billion addressable market opportunity, while states like Pennsylvania and Ohio advance legalization frameworks. This expansion timeline aligns with potential federal relief, creating a dual catalyst scenario that could drive sustained institutional investment into the sector.
Investor positioning suggests the market remains underweight cannabis exposure despite improving fundamentals. Major MSOs have strengthened balance sheets through debt refinancing and operational efficiency gains, while maintaining dominant market positions in high-barrier states. The combination of regulatory catalysts, operational leverage, and compressed valuations creates conditions for a momentum-driven rally that could exceed previous sector peaks as institutional capital returns to cannabis equities.